PharmaBlock Sciences (Nanjing) Overview
- Year Founded
-
2006
- Status
-
Public
- Employees
-
2,593
- Stock Symbol
-
300725
- Investments
-
6
- Share Price
-
$6.44
- (As of Monday Closing)
PharmaBlock Sciences (Nanjing) General Information
Description
Pharma Block Sciences (Nanjing) Inc is a chemistry products and services provider through the pharmaceutical research and development process. Its core business activities include pilot plant and commercial manufacturing of key intermediates and active pharmaceutical ingredient, process development, custom synthesis and building blocks.
Contact Information
Website
www.pharmablock.comCorporate Office
- Number 81 Huasheng Road, Jiangbei New District
- Nanjing, Jiangsu 210032
- China
Corporate Office
- Number 81 Huasheng Road, Jiangbei New District
- Nanjing, Jiangsu 210032
- China
PharmaBlock Sciences (Nanjing) Stock Performance
As of 16-Nov-2026, PharmaBlock Sciences (Nanjing)’s stock price is $6.44. Its current market cap is $1.51B with 234M shares.
(As of Monday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $6.44 | $6.51 | $4.56 - $8.58 | $1.51B | 234M | 21.6M | $0.14 |
PharmaBlock Sciences (Nanjing) Financials Summary
As of 30-Sep-2026, PharmaBlock Sciences (Nanjing) has a trailing 12-month revenue of $318M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 1,763,570 | 1,174,196 | 1,042,105 | 1,189,323 |
| Revenue | 317,668 | 274,564 | 235,333 | 243,849 |
| EBITDA | 35,632 | 52,113 | 60,302 | 55,141 |
| Net Income | 32,144 | 25,550 | 30,596 | 27,896 |
| Total Assets | 810,770 | 1,049,048 | 676,055 | 720,034 |
| Total Debt | 3,779 | 16,104 | 193,697 | 246,682 |
PharmaBlock Sciences (Nanjing) Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
PharmaBlock Sciences (Nanjing) Patents
PharmaBlock Sciences (Nanjing) Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2023109926-A1 | Spirooxindole compound and use thereof in preparation of protease inhibitor as antiviral drug | Inactive | 17-Dec-2021 | ||
| WO-2022242697-A1 | Tyk2 selective inhibitor and use thereof | Inactive | 19-May-2021 | ||
| WO-2022194261-A1 | Pyrimidine-fused cyclic compound and use thereof in preparation of drug for treating pain and spinal cord injury | Inactive | 19-Mar-2021 | ||
| WO-2022179584-A1 | New ezh2 inhibitor and use thereof | Inactive | 26-Feb-2021 | ||
| WO-2022121967-A1 | Egfr tyrosine kinase inhibitor and uses thereof | Inactive | 09-Dec-2020 |
PharmaBlock Sciences (Nanjing) Signals
PharmaBlock Sciences (Nanjing) Investments (6)
PharmaBlock Sciences (Nanjing)’s most recent deal was a Early Stage VC with Pet Medtech. The deal was made on 15-Dec-2024.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Pet Medtech | 15-Dec-2024 | Early Stage VC | Drug Discovery | ||
| ChomiX Biotech | 09-Jan-2022 | Early Stage VC | Discovery Tools (Healthcare) | ||
| Veiglo | 17-Dec-2020 | Later Stage VC | Computers, Parts and Peripherals | ||
| Nanchuang Research Institute | 24-Jun-2019 | Joint Venture | Laboratory Services (Healthcare) | ||
| Huishi | 28-Sep-2018 | Later Stage VC | Specialty Chemicals |
PharmaBlock Sciences (Nanjing) ESG
Risk Overview
Risk Rating
Updated February, 28, 2025
31.24 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,999
Rank
Percentile
Pharmaceuticals
Industry
of 952
Rank
Percentile
Pharmaceuticals
Subindustry
of 438
Rank
Percentile
PharmaBlock Sciences (Nanjing) Exits (1)
PharmaBlock Sciences (Nanjing)’s most recent exit was on 06-Jul-2015 from TransThera. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| TransThera | 06-Jul-2015 | Completed |
|
PharmaBlock Sciences (Nanjing) FAQs
-
When was PharmaBlock Sciences (Nanjing) founded?
PharmaBlock Sciences (Nanjing) was founded in 2006.
-
Where is PharmaBlock Sciences (Nanjing) headquartered?
PharmaBlock Sciences (Nanjing) is headquartered in Nanjing, China.
-
What is the size of PharmaBlock Sciences (Nanjing)?
PharmaBlock Sciences (Nanjing) has 2,593 total employees.
-
What industry is PharmaBlock Sciences (Nanjing) in?
PharmaBlock Sciences (Nanjing)’s primary industry is Specialty Chemicals.
-
Is PharmaBlock Sciences (Nanjing) a private or public company?
PharmaBlock Sciences (Nanjing) is a Public company.
-
What is PharmaBlock Sciences (Nanjing)’s stock symbol?
The ticker symbol for PharmaBlock Sciences (Nanjing) is 300725.
-
What is the current stock price of PharmaBlock Sciences (Nanjing)?
As of 16-Nov-2026 the stock price of PharmaBlock Sciences (Nanjing) is $6.44.
-
What is the current market cap of PharmaBlock Sciences (Nanjing)?
The current market capitalization of PharmaBlock Sciences (Nanjing) is $1.51B.
-
What is PharmaBlock Sciences (Nanjing)’s current revenue?
The trailing twelve month revenue for PharmaBlock Sciences (Nanjing) is $318M.
-
What is PharmaBlock Sciences (Nanjing)’s annual earnings per share (EPS)?
PharmaBlock Sciences (Nanjing)’s EPS for 12 months was $0.14.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process